Patient and Physician Global Disease Assessments in Systemic Sclerosis: Distinct and Complementary Constructs
Authors:
- 24 June 2026
- journal article
- Published by Wiley in Arthritis Care & Research
Abstract
No abstract availableFunding Information
- Santé (380233)
This publication has 13 references indexed in Scilit:
- Immunosuppressive Drug Use in Limited Systemic Sclerosis: An International SurveyArthritis Care & Research, 2026
- Discordance Between Patient and Physician Global Assessments in Early Systemic SclerosisArthritis Care & Research, 2026
- ‘Am I doing this right?’ Physician perceptions of the global assessment in clinical trials of systemic sclerosisRheumatology, 2025
- Comparison of Three Physician Global Assessment Instruments in Systemic SclerosisArthritis Care & Research, 2024
- Patient and Physician Global Assessments of Disease Status in Systemic SclerosisArthritis Care & Research, 2023
- Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaireAnnals of the Rheumatic Diseases, 2022
- New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic SclerosisAnnals of the Rheumatic Diseases, 2021
- “Like No One Is Listening to Me”: A Qualitative Study of Patient–Provider Discordance Between Global Assessments of Disease Activity in Rheumatoid ArthritisArthritis Care & Research, 2017
- What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG)Rheumatology International, 2009
- The value of the health assessment questionnaire and special patient‐generated scales to demonstrate change in systemic sclerosis patients over timeArthritis & Rheumatism, 1997